FDA
-
-
-
-
-
-
-
Precigen Reports Full Year 2025 Financial Results and Business Updates
-
-
-
-
-
-
-
Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respira
-
-
-
-
-
-
-
Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th
-
-
-
-
-
-
-
Biotech outlook for 2025: Stifel
-
-
-
-
-
-
-
Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch
-
-
-
-
-
-
-
JMP Securities Reiterates Market Outperform Rating on Precigen Inc. (PGEN)
-
-
-
-
-
-
-
Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs
-
322,212 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

